At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 88 enrolled
Drug / intervention
TAK-653 Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating TAK-653 Placebo and TAK-653 for Depressive Disorder. Completed, enrolled 88 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of TAK-653 when administered as single and multiple oral doses at escalating dose levels in healthy participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder
CountriesUnited Kingdom
CollaboratorsTakeda
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartAug 2015
First PostedSep 2015
Primary CompletionSep 2017
Study CompletionSep 2017
TodayJul 2026
First PostedSep 25, 2015
Enrollment StartAug 26, 2015
Primary CompletionSep 11, 2017
Study CompletionSep 23, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago
Interventions
TAK-653 Placebodrug
TAK-653 placebo-matching tablets.
TAK-653drug
TAK-653 tablets.